InsiderTrades.com logo
Romulus K. Brazzell net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Romulus Brazzell Biography and Net Worth

Insider of KALA BIO
Dr. Brazzell has served as our Chief Medical Officer since February 2013. He has also served as a Principal of Acuity Advisors, LLC, an ophthalmic consulting company, from January 2014 to July 2018. Dr. Brazzell served as Chief Medical Officer of Mimetogen Pharmaceuticals, Inc., a clinical stage biotechnology company, from January 2012 until December 2015. Dr. Brazzell also held several executive positions at Inspire Pharmaceuticals, Inc., or Inspire, a specialty pharmaceutical company focusing on ophthalmic products, including Executive Vice President of Medical and Scientific Affairs from 2010 to 2011, Executive Vice President and Head of Ophthalmology Business from 2009 to 2010, and Senior Vice President of Ophthalmic Research and Development from 2004 to 2008. Prior to joining Inspire, Dr. Brazzell served as Global Head of Clinical R&D and Senior Vice President, U.S. R&D, of Novartis Ophthalmics AG from 2000 to 2004. Dr. Brazzell also served as Vice President, R&D at Ciba Vision Ophthalmics, Inc. and as Associate Director, R&D, at Alcon Laboratories, Inc. Dr. Brazzell received a B.S. in Pharmacy and a PhD in Pharmaceutical Sciences from the University of Kentucky.

What is Romulus K. Brazzell's net worth?

The estimated net worth of Romulus K. Brazzell is at least $34.66 thousand as of October 22nd, 2025. Dr. Brazzell owns 35,952 shares of KALA BIO stock worth more than $34,658 as of December 5th. This net worth approximation does not reflect any other assets that Dr. Brazzell may own. Learn More about Romulus K. Brazzell's net worth.

How do I contact Romulus K. Brazzell?

The corporate mailing address for Dr. Brazzell and other KALA BIO executives is 490 ARSENAL WAY SUITE 120, WATERTOWN MA, 02472. KALA BIO can also be reached via phone at (781) 996-5252 and via email at [email protected]. Learn More on Romulus K. Brazzell's contact information.

Has Romulus K. Brazzell been buying or selling shares of KALA BIO?

In the last ninety days, Romulus K. Brazzell has sold $38,800.84 in shares of KALA BIO stock. Most recently, Romulus K. Brazzell sold 46,748 shares of the business's stock in a transaction on Wednesday, October 22nd. The shares were sold at an average price of $0.83, for a transaction totalling $38,800.84. Following the completion of the sale, the insider now directly owns 35,952 shares of the company's stock, valued at $29,840.16. Learn More on Romulus K. Brazzell's trading history.

Who are KALA BIO's active insiders?

KALA BIO's insider roster includes Todd Bazemore (COO), Romulus Brazzell (Insider), Hongming Chen (Insider), Mark Iwicki (CEO), and Mary Reumuth (CFO). Learn More on KALA BIO's active insiders.

Are insiders buying or selling shares of KALA BIO?

In the last twelve months, KALA BIO insiders bought shares 1 times. They purchased a total of 310,559 shares worth more than $1,999,999.96. In the last twelve months, insiders at the sold shares 20 times. They sold a total of 1,084,662 shares worth more than $1,539,791.24. The most recent insider tranaction occured on October, 23rd when CFO Mary Reumuth sold 967 shares worth more than $792.94. Insiders at KALA BIO own 8.3% of the company. Learn More about insider trades at KALA BIO.

Information on this page was last updated on 10/23/2025.

Romulus K. Brazzell Insider Trading History at KALA BIO

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/22/2025Sell46,748$0.83$38,800.8435,952View SEC Filing Icon  
6/24/2025Sell5,251$4.01$21,056.5182,698View SEC Filing Icon  
6/3/2025Sell3,687$3.74$13,789.3887,949View SEC Filing Icon  
1/4/2022Sell3,504$1.30$4,555.20View SEC Filing Icon  
See Full Table

Romulus K. Brazzell Buying and Selling Activity at KALA BIO

This chart shows Romulus K Brazzell's buying and selling at KALA BIO by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

KALA BIO Company Overview

KALA BIO logo
KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.
Read More

Today's Range

Now: $0.96
Low: $0.95
High: $1.72

50 Day Range

MA: $1.38
Low: $0.62
High: $19.05

2 Week Range

Now: $0.96
Low: $0.61
High: $20.60

Volume

179,252,385 shs

Average Volume

11,226,258 shs

Market Capitalization

$6.77 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A